MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost

....S. Department of Health and Human Services (HHS). synagis is a biologic medicine known as a monoclonal antib...e or medical insurance, may be eligible to receive synagis at no cost. This marks a significant expansion ove... to receive the established preventive benefits of synagis as prescribed by their doctor at no cost to the fa...

MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV

...nounced results from a recent economic analysis of synagis (palivizumab), a monoclonal antibody (MAb) that is...ion, the analysis evaluated the costs of providing synagis to premature infants, as well as the potential hea...ence is needed to substantiate the linkage between synagis and subsequent reductions in persistent wheezing. ...

MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics

... BACKGROUND: Recent trials have suggested that synagis (palivizumab), a monoclonal antibody (MAb) that is... a cost-effectiveness analysis of prophylaxis with synagis compared with no prophylaxis among preterm infants...ether national guidelines for RSV prophylaxis with synagis are sufficient or whether recommendations should b...

Synagis in Medical Technology

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze by Almost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007 /PRNewswire-FirstCall/ -- Abbott and MedImmune today announced results of a new study, published in the July issue of Journal of Pediatrics, showing that treatment...

Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants

... held this week in Honolulu, HI. About Synagis synagis (palivizumab) is indicated for the prevention of s...rus (RSV) in children at high risk of RSV disease. synagis is given as a shot, usually in the thigh muscle, e...ach month during the RSV season. The first dose of synagis should be given before RSV season begins. Children...

Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

...lanced between treatment groups. About Synagis synagis (palivizumab) is indicated for the prevention of s...rus (RSV) in children at high risk of RSV disease. synagis is given as a shot, usually in the thigh muscle, e...ach month during the RSV season. The first dose of synagis should be given before RSV season begins. Children...

MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV

...ion, the analysis evaluated the costs of providing synagis to premature infants, as well as the potential hea...ence is needed to substantiate the linkage between synagis and subsequent reductions in persistent wheezing. ...high-risk groups. About Synagis(R) (palivizumab) synagis is the only monoclonal antibody approved by the FD...

MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results

...motavizumab appears to have a similar safety and pharmacokinetic profile to synagis (palivizumab) in infants. Additionally, in early phase studies children tre...In its first pivotal trial, which was a head-to-head comparative trial with synagis (palivizumab), motavizumab met its non-inferiority objective by demonstrati...

MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study

...ve a similar safety and pharmacokinetic profile to synagis in infants. Additionally, in early phase studies c...patient management, its secondary endpoint. About synagis synagis is the only monoclonal antibody approved by the FD...

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

...6-percent fewer RSV hospitalizations compared with synagis (p<0.01 for non-inferiority). Additionally, motavi..., compared with 1.9 percent for those who received synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-...[related AEs: motavizumab (N=298, 9.0 percent) vs. synagis (N=258, 7.8 percent) p=not significant (NS); disco...

Synagis in Medical Dictionary

Home health

...ess to nearly 500 nurses, therapists, social workers and home health aides, all of whom are dedicated ... Health Ministry. More Information. synagis Home Management Program. Visiting Nurse Association ... Home care provides the comfort and convenience of health ... Sta- home Health &am...

Synagis in Biological Technology

MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease

...tions (RSVH) among this population. The use of synagis has been restricted, however, due to cost conc...Book guidelines recommend RSV prophylaxis with synagis for infants born between 32 and 35 weeks gestation...lant patients). About Synagis(R) (palivizumab) synagis is the only monoclonal antibody approved by the FD...

MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition

...ost-effectiveness analysis of prophylaxis with synagis compared with no prophylaxis among preterm inf...ether national guidelines for RSV prophylaxis with synagis are sufficient or whether recommendations shou...splant patients). About Synagis(R) (palivizumab) synagis is the only monoclonal antibody approved by the FD...